US EditionGLP-1 Drug Market Changes; Wegovy Pill Hits Shelves; Hypercortisolism Drug Rejected
5 Articles
5 Articles
Novo Nordisk Launches Wegovy Amid Intense Weight-Loss Market
Novo Nordisk has introduced its once-daily Wegovy weight-loss pill in the U.S. priced at $149 per month. The FDA approved the drug last month, aiding Novo's competition against Eli Lilly. Novo anticipates a UK regulator decision on a 25mg Wegovy version by year-end.
GLP-1 Drug Market Changes; Wegovy Pill Hits Shelves; Hypercortisolism Drug Rejected
(MedPage Today) -- A pill formation, a stronger injectable, and more cash payment options: lots of changes are coming to the GLP-1 drug market. (NBC News) The first GLP-1 pill for obesity, semaglutide (Wegovy) tablets from drugmaker Novo Nordisk...
Telehealth companies swoop in to offer Wegovy pill
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Katie Palmer writes: As drugmaker Novo Nordisk launched the pill version of its popular obesity medication Wegovy on Monday, it aimed to capture patients with a cash-pay discount — $149 a month for the lowest starting doses of the medication through A…
Revolutionary launch. The first weight loss pill has been launched on the market. The pill is a variant of the injectable drugs used so far. Currently, the treatment can only be purchased in pharmacies in America. In Romania, four million people are facing an excessive weight. The drugs used for obesity worldwide could be reimbursed in our country this year.
Novo Nordisk began to launch in the United States of the first GLP-1 in the form of a patch for weight loss, Wegovy, opening a new chapter in the treatment of obesity on the American market, reports the CNBC.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
